Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 16 2020 - 12:47PM
via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA),
(“Processa” or the “Company”), a clinical-stage biopharmaceutical
company developing products to improve the survival and/or quality
of life for patients who have unmet medical needs, announced today
that management will participate in two upcoming investor
conferences:
Craig-Hallum Alpha Select Virtual Conference
- Tuesday, Nov. 17,
2020 (one-on-one meetings only)
Benchmark Annual Discovery 1x1 Investor Virtual Conference
- Wednesday, Nov. 18,
2020 (one-on-one meetings only)
To schedule a one-on-one meeting with
management, please contact your conference representative
or James@HaydenIR.com.
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing
clinical evidence of efficacy for patients with unmet or
underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company used these
criteria for selection to further develop its pipeline programs to
achieve high-value milestones effectively and efficiently. Active
pipeline programs include: PCS6422 (metastatic colorectal cancer
and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and
PCS12852 (GI motility/gastroparesis). The members of the Processa
development team have been involved with more than 30 drug
approvals by the FDA (including drug products targeted to orphan
disease conditions) and more than 100 FDA meetings throughout their
careers. For more information, visit the company’s website at
www.ProcessaPharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements
in this press release that are not purely historical are
forward-looking statements which involve risks and uncertainties.
Actual future performance outcomes and results may differ
materially from those expressed in forward-looking statements.
Please refer to the registration statement relating to the
securities being sold in this offering, which identifies important
risk factors which could cause actual results to differ from those
contained in the forward-looking statements.
For More Information: Michael Floyd
mfloyd@processapharma.com 301-651-4256
James Carbonara Hayden IR (646) 755-7412
james@haydenir.com
Corporate Communications:
InvestorBrandNetwork (IBN) Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Apr 2023 to Apr 2024